The pharmaceutical company AstraZeneca has reportedly started negotiations to merge with Bristol Myers Squibb, one of its main competitors. The resulting company would have a market capitalization of $400 billion, the fourth highest in the entire pharmaceutical sector.
However, it is not certain that the negotiations will be successful. AstraZeneca is Britain’s second-largest company by value and would merge with a smaller but still sizable US company. This type of operation must take into account different interests, which do not always converge, between the shareholders and owners of the companies involved.
The merger between AstraZeneca and Bristol Myers Squibb
The news of the ongoing negotiations between AstraZeneca and Bristol Myers Squibb was first to report FinancialTimeswhich clarified some fundamental points. The negotiations have been going on for months, but they are still in the preliminary phase. The two companies have not confirmed the rumor.
If the operation were successful, the fourth pharmaceutical company in the world would be born. The market value would be close to 400 billion dollars. The new reality would have one of the most varied drug offerings on the market, with many specific categories covered by patents still valid for decades.
What a company AstraZeneca is
AstraZeneca has become famous in recent years for its Covid-19 vaccine, but it is one of the largest pharmaceutical companies in the world. His fields of specialization are in particular:
- oncology, the treatment of tumors;
- cardiovascular diseases, which affect the heart and blood vessels;
- respiratory diseases.
AstraZeneca is in full financial health, with earnings growing to $2.63 per share and revenues of $30 billion in the first half of 2026.
What company is Bristol Myers Squibb
BMS, on the other hand, has different specializations from those of AstraZeneca. It is among the most important global pharmaceutical companies in the field of immuno-oncology, the branch of medicine that studies the immune system in its behavior towards tumor cells. It also has an important presence in segments such as:
- hematology, the medical discipline that deals with blood;
- immunology, which concerns the immune system;
- cardiovascular diseases.
There are therefore elements of overlap between the two companies, but in general Bms and AZ deal with rather different fields. Bristol Myers Squibb performed strongly, with earnings per share of $2.04 in the second quarter and more than $24 billion in revenue in the first half of 2026.
What can go wrong in the merger between AstraZeneca and BMS
Corporate mergers, especially if they are this large, are extremely complex operations that often fail before they materialize. The negotiations concern many aspects, both practical, administrative and economic. In the case of the merger between AstraZeneca and BMS, the obstacles to overcome are:
- clearance from UK and US antitrust authorities;
- the European Commission’s examination of the impact on the EU market.
The British CMA, the London antitrust authority, will in particular have to understand the fate of the new reality that would arise from the merger. AstraZeneca is the second largest British company by market capitalisation. Accepting US control of the new reality would be complicated for the British authorities.
